{"id":"matched-placebo-for-tafenoquine","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemolysis"},{"rate":"null","effect":"Neuropsychiatric events"},{"rate":"null","effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tafenoquine is a blood schizonticide that inhibits the parasite's ability to detoxify heme, ultimately leading to the parasite's death. This mechanism of action is thought to be responsible for the drug's efficacy against Plasmodium species.","oneSentence":"Tafenoquine is an antimalarial drug that works by targeting the parasite's heme detoxification pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:11.263Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae"},{"name":"Prevention of malaria caused by Plasmodium falciparum"}]},"trialDetails":[{"nctId":"NCT05947812","phase":"PHASE2","title":"A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression","status":"UNKNOWN","sponsor":"60P Australia Pty Ltd","startDate":"2023-08-01","conditions":"COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2","enrollment":148},{"nctId":"NCT02802501","phase":"PHASE3","title":"Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-08","conditions":"Malaria, Vivax","enrollment":150},{"nctId":"NCT02216123","phase":"PHASE3","title":"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-30","conditions":"Malaria, Vivax","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matched-Placebo for Tafenoquine","genericName":"Matched-Placebo for Tafenoquine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafenoquine is an antimalarial drug that works by targeting the parasite's heme detoxification pathway. Used for Treatment of malaria caused by Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae, Prevention of malaria caused by Plasmodium falciparum.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}